| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product sales, net | 3,195 | 3,307 | 3,256 | NaN |
| Cost of goods sold | 1,633 | 1,636 | 1,677 | NaN |
| Gross profit | 1,562 | 1,671 | 1,579 | NaN |
| Research and development expense | 18 | 18 | 24 | NaN |
| Sales expense | 673 | 663 | 691 | NaN |
| Marketing expense | 401 | 418 | 429 | NaN |
| General and administrative expense | 788 | 647 | 710 | NaN |
| Benefit from reversal of accrued payroll taxes | 0 | 0 | 0 | NaN |
| Total operating expenses | 1,880 | 1,746 | 1,854 | NaN |
| Operating income (loss) | -318 | -75 | -275 | NaN |
| Gain on extinguishment of debt | 20 | NaN | 0 | NaN |
| Change in fair value of convertible notes | 252 | NaN | NaN | NaN |
| Other expense, net | NaN | -91 | -107 | NaN |
| Interest expense, net | 93 | NaN | NaN | NaN |
| Loss before income taxes | -643 | -204 | -382 | NaN |
| Income tax expense | 0 | 2 | 0 | NaN |
| Net loss | -643 | -206 | -382 | -370 |
| Depreciation and amortization | 23 | 21 | 31 | 140 |
| Stock-based compensation | 148 | 123 | 124 | 250 |
| Amortization of debt discount | 91 | 127 | 107 | 279 |
| Amortization of right of use assets | 65 | 63 | 63 | 112 |
| Gain in fair value of contingent consideration liabilities | NaN | 0 | 0 | NaN |
| Fair value adjustment for convertible notes payable | -252 | NaN | NaN | NaN |
| Gain on debt extinguishment | 20 | 0 | 0 | 38 |
| Benefit from reversal of accrued payroll tax (note 11) | 0 | 0 | 0 | -522 |
| Deferred taxes | NaN | -3 | NaN | NaN |
| Other | -12 | 10 | 23 | 105 |
| Accounts receivable, net | -22 | 6 | -142 | 12 |
| Inventory | -174 | 3 | -132 | -698 |
| Prepaid expenses and other | 28 | -25 | -64 | -77 |
| Accounts payable and accrued expenses | 92 | -266 | -563 | -513 |
| Operating lease liability | -63 | -245 | NaN | NaN |
| Net cash flows provided by (used in) operating activities | 101 | -307 | -306 | 206 |
| Purchases of property and equipment | 3 | 9 | 11 | 89 |
| Acquisition of business, net of cash acquired | NaN | 0 | 0 | 0 |
| Net cash flows used in investing activities | -3 | -9 | -11 | -89 |
| Proceeds from note payable | 0 | 450 | 0 | 1,200 |
| Debt issuance costs related to note payable | 15 | 8 | 0 | 82 |
| Repayment of note payable | 0 | 150 | 214 | 686 |
| Repayment of unsecured debt | 53 | 34 | 20 | 119 |
| Net cash flows provided by (used in) financing activities | -68 | 258 | -234 | 313 |
| Effect of exchange rate changes on cash | 1 | 2 | -1 | 2 |
| Net increase in cash | 31 | -103 | -505 | 432 |
| Cash, beginning of period | 278 | 381 | 454 | NaN |
| Cash, end of period | 309 | 278 | 381 | NaN |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)